A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a (ANRS EP63)
研究概览
详细说明
Objectives
Principal objective
To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients who have participated in the ANRS 139 TRIO trial, always followed and in virological success, and carrying multi-resistant viruses archived in the HIV cell reservoir, in order to reconstruct the chronology of the installation of this reservoir.
Secondary objectives
To analyze the HIV viral sequences present in the CD4 + lymphocytes with other membrane HIV reservoir markers, currently being identified, in these same patients
Methodology
Pathophysiological study, in patients infected by multi drug-resistant viruses
Estimated enrollment
21 participants (total and per group)
Intervention
167mL blood sample in EDTA tube:
- 160mL (16 tubes of 10mL): for IGH (Institute of Human Genetics-Montpellier)
- 7mL (1tube of 7mL): to measure HIV-RNA in centers
Estimated planning or Study / Trial timetable
Study start date: September 2017
Enrollment period: 12 months
Total study duration: 24 months (analyses included)
Estimated study/trial completion date: September 2019 (one year after enrollment of the last patient)
Study design
Cross-sectional survey, 167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Montpellier、法国
- Monsef BENKIRANE
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients who participated to ANRS139 TRIO trial, and still followed in centers
- Who remained in virological success since the participation at the trial: 90% of HIV-1 RNA level less than 50 copies/mL : one or more blips less than 1000 copies/mL are tolerated
- Genotypic resistance profiles available at baseline and before trial
- Age ≥ 18 years
- Affiliate or beneficiary of a social security system (the State Medical Aid or AME is not a social security system).
- Written informed consent signed by the person and the investigator before any exam performed in the study.
Exclusion Criteria:
- HIV-1 RNA level ≥ 1000 copies/mL at least once since the end of the 139 TRIO trial
- Patient participating in another research evaluating other treatments with an exclusion period ongoing at the screening visit.
- Person under legal guardianship or deprived of liberty by a judicial or administrative decision.
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Presence of HIV viral sequences in the CD32 + CD4a + T lymphocytes of the patients
大体时间:inclusion
|
inclusion
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
艾滋病毒感染的临床试验
-
Hospital Clinic of Barcelona完全的
-
Centers for Disease Control and PreventionGilead Sciences; CDC Foundation完全的
-
Rajavithi Hospital未知研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的免疫状态 | 研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的 HIV 病毒载量泰国
-
National Institute of Allergy and Infectious Diseases...完全的HIV-1 感染 | HIV抗体 | 中和抗体 | 病毒载量 | 单克隆抗体美国
-
AIDS Healthcare FoundationUniversity of California, Los Angeles完全的
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University of Bergen; Centre... 和其他合作者完全的
-
Hospital Universitari Vall d'Hebron Research InstituteGilead Sciences完全的
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixa完全的